The IPO Buzz: MBX Biosciences (MBX Proposed) Sets Terms & Launches $127.5 Million IPO
MBX Biosciences (MBX Proposed), a Phase 2 biotech targeting endocrine and metabolic diseases, disclosed the terms for its $127.5 million IPO and launched the deal early today – Monday, Sept. 9, 2024 – for pricing later this week. MBX Biosciences Inc. is offering 8.5 million shares at a price range of $14.00 to $16.00 to […]
September 9, 2024 Read More